Efficacy and safety of topical Streptococcus postbiotic emollient in adolescents and adults with mild-to-moderate atopic dermatitis: A randomized, double-blind, vehicle-controlled trial

Min Seo Kim¹, Hyeon Jin Kim^{2

3}, So Min Kang², Young Mok Heo^{4

5}, Jiseung Kang^{6

7}, Tae Kyeong Ryu², Hyun Jeong Kim², Young-Bong Choi⁸, Sol Kim^{4

5}, Youn Hwa Nho^{4

5}, Seunghyun Kang^{4

5}, Lee Smith⁹, Ai Koyanagi¹⁰, Nikolaos G Papadopoulos^{11

12}, Hyungwoo Jo^{4

5}, Dong-Geol Lee^{4

5}, Jung U Shin¹³, Dong Keon Yon^{2

3

14}

Affiliations

¹ Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
² Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.
³ Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
⁴ Research and Innovation Center, Cosmax BTI, Seoungnam, South Korea.
⁵ Department of Microbiology, Dankook University, Cheonan, South Korea.
⁶ Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁷ Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.
⁸ Department of Chemistry, Dankook University, Cheonan, South Korea.
⁹ Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.
¹⁰ Research and Development Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.
¹¹ Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.
¹² Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty or Biology, Medicine and Health, The University of Manchester, Manchester, UK.
¹³ Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
¹⁴ Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.

Randomized Controlled Trial

Min Seo Kim et al. Allergy. 2024 Jun.

. 2024 Jun;79(6):1612-1616.

doi: 10.1111/all.16077. Epub 2024 Mar 4.

¹ Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
² Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.
³ Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
⁴ Research and Innovation Center, Cosmax BTI, Seoungnam, South Korea.
⁵ Department of Microbiology, Dankook University, Cheonan, South Korea.
⁶ Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁷ Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.
⁸ Department of Chemistry, Dankook University, Cheonan, South Korea.
⁹ Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.
¹⁰ Research and Development Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.
¹¹ Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.
¹² Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty or Biology, Medicine and Health, The University of Manchester, Manchester, UK.
¹³ Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
¹⁴ Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.

No abstract available

References

1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.
1. Clausen M‐L, Agner T, Lilje B, Edslev SM, Johannesen TB, Andersen PS. Association of disease severity with skin microbiome and filaggrin gene mutations in adult atopic dermatitis. JAMA Dermatol. 2018;154(3):293‐300.
1. Kim G, Kim M, Kim M, et al. Spermidine‐induced recovery of human dermal structure and barrier function by skin microbiome. Commun Biol. 2021;4(1):231.
1. Schmid‐Grendelmeier P, Gooderham MJ, Hartmann K, et al. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies. Allergy. 2023;79:174‐183.
1. Park CW, Kim BJ, Lee YW, et al. Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: phase 3, randomized, vehicle‐controlled study (CAPTAIN‐AD). J Allergy Clin Immunol. 2022;149(4):1340‐1347.e4.